Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CANbridge Pharmaceuticals Inc.
北海康成製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1228)

VOLUNTARY ANNOUNCEMENT
GAURUNNING® AND LIVMARLI® INCLUDED IN THE FIRST EDITION OF COMMERCIAL HEALTH INSURANCE DRUG COVERAGE COST TABLE

This announcement is made by CANbridge Pharmaceuticals Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to update the shareholders and potential investors of the Company on the latest business development of the Group in relation to the inclusion of Gaurunning® (velaglucerase-beta for injection) ("**Gaurunning**") and Livmarli® (maralixibat oral solution) ("**Livmarli**") in the industry's first edition of Commercial Health Insurance Drug Coverage Cost Table (the "**Cost Table**").

The board of directors (the "**Board**") of the Company is pleased to announce that Gaurunning and Livmarli have been included in the Cost Table released by the China Association of Actuaries on November 10, 2026. The Cost Table covers 117 drugs across multiple therapeutic areas including oncology, rare diseases, and chronic diseases, with the aim of strengthening the pricing foundation for innovative drug coverage. Gaurunning and Livmarli have both been included in the Cost Table, covering three rare disease indications, namely Gaucher disease, Alagille syndrome ("**ALGS**") and progressive familial intrahepatic cholestasis ("**PFIC**"). This inclusion is expected to broaden commercial insurance coverage pathways for rare disease patients and reduce their medication burden.

Gaurunning obtained marketing approval from National Medical Products Administration ("**NMPA**") of the People's Republic of China ("**China**") on May 13, 2025. It is the first long-term enzyme replacement therapy (ERT) independently developed in China for adolescents aged 12 and above and adults with Type I and Type III Gaucher disease. As an innovative biologic drug, Gaurunning is positioned as an alternative to comparable imported products. Its expected lower treatment cost is poised to substantially reduce patients' long-term financial burden and fundamentally improve the accessibility and sustainability of therapy for Gaucher disease patients worldwide. The Company holds global proprietary rights to develop and commercialize the product, and the first overseas market entered into by the product is the growing North African market. In addition, an NMPA-approved registrational trial is ongoing, aiming to expand Gaurunning's label to children aged 2 to 12 years.

Livmarli is a minimally absorbed ileal bile acid transporter inhibitor that blocks the enterohepatic circulation of bile acids, reduces hepatic and serum bile acid levels, mitigates resultant liver injury and relieves cholestatic pruritus (extreme itching). As the first product approved in China for the treatment of ALGS and PFIC in patients aged 3 months and older, Livmarli was launched commercially in mainland China in 2024. To date, it has been included in commercial insurance programmes in 64 cities, covering a population of 299 million in China. On August 14, 2026, Livmarli obtained reimbursement approval from the National Health Insurance Administration of Taiwan, with the reimbursement coverage effective September 1, 2026.

The Company considers that the inclusion of Gaurunning and Livmarli in the Cost Table marks a milestone in the Company's efforts to advance multi-tiered coverage and access for rare diseases, and provides reference pricing information for the design of commercial health insurance products. The Company looks forward to leveraging this industry platform to open up commercial insurance coverage pathways and to further enhance access to medicines for rare disease patients.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
CANbridge Pharmaceuticals Inc.
Dr. James Qun Xue
Chairman

Hong Kong, November 16, 2026

As of the date of this announcement, the Board comprises Dr. James Qun Xue as executive Director; Ms. Wei Zhao and Mr. Tingwei Wang as non-executive Directors; and Dr. Richard Arthur Moscicki, Mr. James Arthur Geraghty, Mr. Peng Kuan Chan and Dr. Lan Hu as independent non-executive Directors.